2Q 2017 PERFORMANCE

FINANCIAL RESULTS BUSINESS HIGHLIGHTS

SALES WORLDWIDE 1 Medical Devices

+2.9 % $
6.6BN
Strong 2Q17 growth for: NEUROMODULATION New Diabetes
becomes NUMBER 1 Collaboration:
DIABETES
for treating chronic
ON COMPARABLE
ELECTROPHYSIOLOGY pain through spinal and
OPERATIONAL BASIS* STRUCTURAL HEART stimulation
NEUROMODULATION

RAISED FULL-YEAR 2017 GUIDANCE

$2.43 to $2.53 Adjusted EPS, reflecting double-digit growth.2
Product Milestones
BUSINESS SEGMENT SALES EUROPEAN LAUNCHES
Confirm RXTM Insertable Cardiac Monitor (ICM)
DIAGNOSTICS NUTRITION helps physicians remotely diagnose and treat difficult
to detect irregular heartbeats (cardiac arrhythmias).**

Alinity hq hematology system improves efficiencies

for high-volume labs. It is the fifth new diagnostic system

$
1.3BN $
1.7BN
launched in Europe since November 2016.**

CANADIAN APPROVAL
FreeStyle Libre, a revolutionary continuous glucose
ESTABLISHED monitoring system for people with diabetes.**
MEDICAL DEVICES PHARMACEUTICALS

SUBMITTED FOR FDA APPROVAL

MRI-conditional labeling for the Quadra AssuraTM

2.6BN 1.0BN
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
$ $ will allow heart failure patients to undergo full body MRI
scans, if required.**

*Comparable operational results are non-GAAP and include the prior year results for St. Jude Medical, and exclude the impact of exchange and prior and current year results for divested businesses. For full financial data and
reconciliation of non-GAAP measures, please see our press release dated July 20, 2017.
**Not available for sale in the United States.
Reported sales +24.4% 2Full-year 2017 GAAP EPS guidance of $1.03 to $1.13
1

FORWARD-LOOKING STATEMENTS
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbotts operations
are discussed in Item 1A, Risk Factors to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no obligation to release
publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

ABBOTT.COM @ABBOTTNEWS; @ABBOTTGLOBAL ABBOTTGLOBAL ABBOTT